



CONFIDENTIAL Property of Palmetto Infusion Services / CONFIDENTIAL Property of Palmetto Infusion Services / CONFIDENTIAL Property of Palmetto Infusion Services

MRN: _____

DOB: _____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

STANDARD Lemtrada® (alemtuzumab) PLAN OF TREATMENT

(Re) Certification Period From _____ to _____

NOTE: Patient **may be ineligible** to receive alemtuzumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, severe abdominal pain or vomiting, and/or surgery.

1. Patient Name: _____ Height (inches): _____ Weight (lbs): _____

2. Allergies: _____

3. Diagnosis: G35 Relapsing Multiple Sclerosis

4. Pre-medications: None or Administered at minimum of 30-60 minutes prior to infusion **as selected:**

** Premedication of Acetaminophen PO, Diphenhydramine IVP, and Ondansetron IVP is suggested prior to infusion*

<p>Acetaminophen:</p> <p><input type="checkbox"/> 1000 mg PO</p> <p><input type="checkbox"/> 650 mg PO</p> <p><input type="checkbox"/> 500 mg PO</p> <p><input type="checkbox"/> 325 mg PO</p>	<p>Diphenhydramine: <input type="checkbox"/> 25 mg IVP, <input type="checkbox"/> 50mg IVP, <input type="checkbox"/> 25 mg PO, <input type="checkbox"/> 50mg PO or</p> <p>Alternate oral antihistamine to diphenhydramine:</p> <p><input type="checkbox"/> Cetirizine 10 mg <input type="checkbox"/> Loratadine 10 mg <input type="checkbox"/> Fexofenadine <input type="checkbox"/> 60mg or <input type="checkbox"/> 180mg</p> <p>Famotidine: <input type="checkbox"/> 20mgs PO, <input type="checkbox"/> 40mgs PO, <input type="checkbox"/> 20mgs IVP, <input type="checkbox"/> 40mgs IVP</p> <p>Ondansetron: <input type="checkbox"/> 4 mg IVP, <input type="checkbox"/> 4 mg PO, <input type="checkbox"/> other: _____</p>
---	---

Pre-medicate with other: _____

CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion

5. Orders:

Methylprednisolone 1000 mg IV over 1 hour in Sodium Chloride 0.9% diluted per protocol for the **first 3 days of each treatment course** prior to Lemtrada®

Lemtrada® (alemtuzumab) 12 mg IV in 100 ml of Sodium Chloride 0.9% to infuse over 4 hours, followed by **(2) two hour post infusion monitoring after each dose.**

6. Frequency:

_____ First treatment course: daily x 5 consecutive days or

_____ Second treatment course: daily x 3 consecutive days

Special orders: _____

If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES

7. Physician's Signature: _____ / _____ Date: _____
No Stamp Signatures (Dispense as written) (Substitution permitted)

Printed Physician's Name with Credentials: _____ NPI: _____

8. Fax updated supporting clinical MD notes with each order renewal or change in orders

Infusion order forms and Adverse Drug Reaction Guidelines are available at www.palmettoinfusion.com



MRN: _____

DOB: _____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

Guidelines for Prescribing Lemtrada® (alemtuzumab)

(Required documentation with all initial referrals)

Patient Name: _____

Referral Date: _____

Because of the risk of autoimmunity, infusion reactions, and malignancies, LEMTRADA is available only through restricted distribution under a Risk Evaluation Mitigation Strategy (REMS) Program. Call 1-855-676-6326 to enroll in the LEMTRADA® REMS program.

Include signed and completed **Plan of Treatment**. (MD must complete sections 1-8); (Infusion order forms & Standard Adverse Reactions orders are available at www.palmettoinfusion.com under Agency/MD tab)

Include patient demographic information and insurance information. (Copy of insurance cards if available)

Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.
• LEMTRADA® is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

If patient is switching biological therapies, then MD must specify wash-out period prior to starting Lemtrada® as specified of _____ weeks. Last known biological therapy: _____ and last date received: _____.

Pre-Screening: (* TB screening results must be available prior to start of therapy and within last 12 months. If screening results are positive or indeterminate, then a negative CXR result is required.)

- Has antiviral prophylaxis for herpetic viral infections been prescribed? Yes No
- Are immunizations current and if any recently given, were they at least 6 weeks prior to start of Lemtrada? Yes No
- Required TB screening results: PPD or QuantiFERON Gold Test.*
- CBC with differential, serum creatinine level, urinalysis with urine cell counts, & TSH levels prior to start of therapy.

**** Warnings/Precautions:** • LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia (ITP) and anti-glomerular basement membrane disease. • **Clinical Lab Monitoring:** Monitor complete blood counts with differential, serum creatinine levels, and urinalysis with urine cell counts and thyroid stimulating hormone (TSH) prior to start of therapy and at periodic intervals for 48 months after the last dose. • **Life threatening infusion reactions:** Monitor patients for two hours after each infusion. Make patients aware that serious infusion reactions can also occur after the 2-hour monitoring period. • LEMTRADA may cause an increased risk of malignancies, including thyroid cancer, melanoma, and lymphoproliferative disorders. Perform baseline and yearly skin exams. • **Adverse Reactions:** Most common (incidence ≥10% and > interferon beta-1a): rash, headache, pyrexia, nasopharyngitis, nausea, urinary tract infection, fatigue, insomnia, upper respiratory tract infection, herpes viral infection, urticaria, pruritus, thyroid gland disorders, fungal infection, arthralgia, pain in extremity, back pain, diarrhea, sinusitis, oropharyngeal pain, paresthesia, dizziness, abdominal pain, flushing, and vomiting. • **Contraindicated** in patients who are infected with Human Immunodeficiency Virus (HIV) because LEMTRADA causes prolonged reductions of CD4+ lymphocyte counts. • **Pregnancy Category C.** See full prescribing information.

Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.

Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.